Purpose: We evaluated predictive factors for compensatory hypertrophy and renal outcomes in a large cohort of patients with multicystic dysplastic kidneys. Materials and Methods: We conducted a retrospective review from 1997 to 2016. Contralateral kidney and multicystic dysplastic kidney length were recorded from all ultrasounds as well as creatinine when available. We used generalized estimating equations to determine predictors of contralateral kidney length. Results: A total of 443 children with multicystic dysplastic kidneys were identified based on sonographic findings and lack of function on nuclear scan. Average followup was 3.2 years (IQR 1.5 to 5.7). Median time to involution in patients diagnosed before age 2 years was 5.5 years (95% CI 3.8e7.0). In all patients the median time to contralateral hypertrophy was 2.7 years (95% CI 2.2e3.3), and 90% of patients manifested contralateral hypertrophy by 10 years. After adjusting for age, gender, multicystic dysplastic kidney side and cohort status for each year of involution after age 2 years, the contralateral kidney grows 0.35 cm longer (95% CI 0.01e0.68, p ¼ 0.04) compared to cases without involution. Patients with contralateral hypertrophy had greater creatinine clearance at followup (83 vs 61 ml per minute, p ¼ 0.07), although this finding was not statistically significant due to limited data. Conclusions: The majority of children with multicystic dysplastic kidneys will have contralateral hypertrophy by age 3 years. Multicystic dysplastic kidney involution predicts contralateral kidney growth rate after age 2 years. A small cohort of patients with multicystic dysplastic kidneys will not exhibit contralateral hypertrophy and may be at risk for renal insufficiency.
MULTICYSTIC dysplastic kidney disease is a form of renal cystic dysplasia that is commonly detected on prenatal ultrasound. 1 Conservative management of children with multicystic dysplastic kidneys is recommended as the natural history of the disease is generally benign. 2 Recent systematic reviews have demonstrated that multicystic dysplastic kidney is not associated with hypertension or Wilms tumor. 3, 4 Despite these findings, patients often are followed long term, and associated yearly costs for serial ultrasounds are estimated to be approximately $8 million to $10 million for every 1,000 children with multicystic dysplastic kidneys. 5 
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* Which patients with MCDK require long-term followup is currently debated since renal impairment or insufficiency may develop in a small subset. 6, 7 Contralateral kidney hypertrophy is thought to be an indication of renal health and occurs in about a quarter of patients at birth. 8 A previous analysis of patients with MCDK showed that when evaluating the contralateral kidney, compensatory hypertrophy is observed in 77% at followup and is directly correlated with involution of MCDK. 9 In that review of 61 patients it was surmised that followup ultrasounds provided little information and urological followup was unnecessary. To overcome these limitations, we retrospectively analyzed a large cohort of patients with MCDK with long-term followup to evaluate predictive factors (including MCDK involution) for compensatory hypertrophy. The results of this study may provide more focused knowledge of subgroups at risk for renal insufficiency.
PATIENTS AND METHODS
Study Sample
We retrospectively reviewed medical charts of 451 patients diagnosed with "dysplastic kidney" from a radiographic research database at 2 large pediatric tertiary care centers in the San Francisco Bay Area. We searched the database for all the years data were available (1997 to 2016). All cases of MCDK were confirmed via sonography. Eight patients with segmental dysplasia, bilateral cystic disease and cystic dysplasia associated with ureteroceles or duplicated systems were excluded from analysis. Patients entered the study at the first postnatal ultrasound. Followup was defined as the latest ultrasound date in our database.
We collected demographic and clinical characteristics listed in table 1. All patients who underwent renal nuclear scan exhibited less than 10% function in the affected kidney. We recorded all MCDK and contralateral kidney lengths from ultrasounds available in the database. Involution status was defined as undetectable evidence of the MCDK on ultrasound. The first ultrasound date that demonstrated involution was used to determine the time to involution. Finally, we collected height, weight and creatinine when available from clinic and laboratory notes. Creatinine clearance was calculated in all patients with a followup creatinine. 10 The majority of patients were diagnosed before age 2 years (74%), and the remainder entered our study after age 2 years. Because records of these patients from earlier years were unobtainable, we performed sensitivity analyses to ensure data quality.
Statistical Analysis
All analyses were performed using STATAÒ, version 13. We used Student t-tests and chi-square tests to compare continuous and categorical variables, respectively. Continuous variables that were not normally distributed (ie creatinine clearance at followup) were compared using the Mann-Whitney U test. Kaplan-Meier curves were constructed for 2 separate outcomes, involution of the MCDK and contralateral hypertrophy. Contralateral hypertrophy was defined as 2 standard deviations above mean kidney length by age. 11, 12 Patients entered the analysis at diagnosis and remained until an event occurred or we no longer had sonographic data for them, at which time they were censored. We constructed separate and combined Kaplan-Meier curves to visually inspect differences between those who entered the study before and after age 2 years. We randomly selected approximately 10% of our sample to assess whether contralateral hypertrophy was a consistent finding.
Predictors of Involution and Hypertrophy
We used Cox proportional hazard models to determine the rate of involution and contralateral hypertrophy. We tested MCDK length at diagnosis, contralateral kidney length at diagnosis, gender and side. These predictors were selected a priori based on previous research. 13, 14 For all time to event analyses patients were excluded who experienced the event during study entry (ie involution or contralateral hypertrophy). We then used GEEs to model contralateral kidney length due to the longitudinal aspect of the data. 15 We aimed to determine if MCDK involution is associated with contralateral kidney growth after controlling for the previously mentioned factors. Because kidney growth is rapid within the first few years of life, we used linear splines to determine the natural cutoff age within the data set (1.9 years), from which we developed separate models to test for interactions. Robust confidence intervals were obtained within the GEE model. 16 Any 
Time to Involution
Median time to involution in patients diagnosed before age 2 years was 5.5 years (95% CI 3.8e7.0), while the median time to involution for patients diagnosed after age 2 years was 2.7 years (95% CI 2.0e5.6, supplementary figure, http://jurology.com/). Thus, the median time to involution from diagnosis in the entire sample was 4.9 years (95% CI 3.6e6.4, fig. 1 ). The cumulative probability of involution was approximately 14% at age 1 year, 28% at 2 years, 50% at 5 years and 75% at 10 years. We observed no patient who underwent involution after approximately age 10 years. Regardless of cohort status, the smaller the length of the MCDK kidney at diagnosis, the faster the rate of involution. Of patients diagnosed before age 2 years the rate of involution was 1.29 times as fast (95% CI 1.17e1.41) in those with 1 cm less MCDK length at diagnosis. Contralateral kidney length, gender and side were not associated with time to involution (table 2).
Time to Contralateral Hypertrophy
Median time to contralateral hypertrophy for patients diagnosed before age 2 years was 2.7 years (95% CI 2.2e3.3). Similarly the median time to contralateral hypertrophy for patients diagnosed after age 2 years was 2.7 years (CI not determined due to small sample size, data not shown). In all patients the median time to contralateral hypertrophy was 2.7 years (95% CI 2.2e3.3), and 90% of patients had experienced contralateral hypertrophy by 10 years ( fig. 2) . Thus, the cumulative probability of contralateral hypertrophy was approximately 19% at age 1 year, 38% at 2 years, 70% at 5 years and 90% at 10 years. MCDK and contralateral kidney length, gender and side were not associated with time to contralateral hypertrophy (table 2). In the 10% random sample of our cohort contralateral hypertrophy was a consistent finding throughout followup after it was first documented.
Creatinine Clearance and Kidney Length
Creatinine clearance was calculated in 43 patients. Median age at followup for these patients was 6 years (range 3 to 12). Patients who manifested contralateral hypertrophy during the study had greater creatinine clearance (median 83 ml per minute, IQR 68 to 138) than those who did not exhibit contralateral hypertrophy (median 61, IQR 57 to 76), although this finding did not reach statistical significance (p ¼ 0.07).
A total of 1,238 ultrasounds of contralateral kidney lengths were analyzed. Figure 3 illustrates contralateral kidney length plotted by age in years for both cohorts. After adjusting for age, gender, MCDK side and cohort status for each year a patient had experienced involution after age 2 years the contralateral kidney grew 0.35 cm longer (95% CI 0.01e0.68, p ¼ 0.04) compared to patients without involution. Involution status before age 2 years did not predict contralateral growth (0.14 cm, 95% CI À0.13e0.40).
DISCUSSION
Most patients with MCDK had contralateral hypertrophy by age 3 years, and a small minority (approximately 10%) did not exhibit any contralateral hypertrophy during the study. Involution status predicts contralateral kidney growth after age 2 years. The mechanism and temporal relationship 17 If compensatory hypertrophy has occurred by age 3 years with a stable MCDK, then further monitoring by sonography is unnecessary. This process leaves a small cohort of patients with MCDK by age 3 years who have not manifested contralateral hypertrophy. In this minority cohort ultrasound at age 3 years or later could help stratify which patients do not have contralateral hypertrophy and thus may be at risk for renal insufficiency (supplementary table 2, http://jurology.com/).
This recommendation is consistent with the findings of Onal and Kogan, who observed contralateral hypertrophy in 77% of patients, which was directly correlated with MCKD involution. 9 Compensatory hypertrophy is common in patients with MCDK but it does not occur in all patients. 18e20 In a prospective cohort of 43 patients with MCDK 35 (81%) exhibited compensatory hypertrophy at 10 years of followup. 18 In our study the time to event analysis revealed that about 90% of patients had compensatory hypertrophy by 10 years after diagnosis, leaving approximately 10% of patients without compensatory hypertrophy. Whether this situation puts patients at risk for renal insufficiency is not well understood. However, renal length has been linked to glomerular filtration rate, 21, 22 and we provide inconclusive evidence that patients with compensatory hypertrophy have increased creatinine clearance. Additional studies are required to confirm this finding.
Once a patient has documented hypertrophy, the hypertrophy appears to be a consistent finding. If a patient presents later in childhood with a history of MCDK and renal status is not documented, comparative data based on sonographic renal lengths can be used to determine if contralateral hypertrophy, and hence low risk of renal insufficiency, is present (supplementary table 2, http:// jurology.com/). If the child continues without hypertrophy, and especially without involution, monitoring of blood pressure and proteinuria may be required with referral to nephrology. Whether contralateral hypertrophy remains in adulthood is unknown. Additionally hypertrophy could be a sign of glomerular hyperfiltration, which in the long term could actually lead to renal insufficiency. We did not see evidence of glomerular hyperfiltration in our cohort. Longer followup in adults with MCDK would allow exploration of this possibility. No baseline factors in our study predicted the rate of contralateral hypertrophy. However, patients with involution had greater contralateral kidney growth after age 2 years compared to those without involution. Reasons for this result may be that inherent renal growth factors at the beginning of life outweigh the influence of the MCDK kidney as even in nonpathological kidneys much growth occurs in the first few years of life. 11, 23 MCDK involution may invoke changes in a humoral substance that controls renal hypertrophy, or a persistent dysplastic kidney may act as a "vascular steal," preventing contralateral growth. 24 As noted, smaller MCDK kidneys at diagnosis involute faster. We replicated this finding from many studies demonstrating that length of MCDK at diagnosis predicts involution status. 13, 14, 25, 26 Associated urological and other congenital anomalies are common in patients with MCDK. In a systematic review of patients with MCDK associated anomalies occurred in 14%, which is similar to our findings. 20, 27 Reflux has been reported to range from 4% to 28% in patients with MCDK. 20, 28 Few patients in our cohort had reflux, a finding that may be due to missing data. The influence of reflux on compensatory hypertrophy and MCDK involution is not completely known, although 1 report showed an association between reflux and smaller contralateral kidneys during the first year of life. 29 Embryologically since the fetal kidneys and m€ ullerian structures form in close proximity regarding time and space, one might expect to see an increase in m€ ullerian abnormalities in postpubertal females with MCDK. In our cohort of 23 females followed beyond age 10 years we did not see any significant m€ ullerian abnormalities, suggesting that sonographic evaluation of postpubertal girls with MCDK should not be routinely performed, but should be reserved for those with symptoms suggestive of abnormal menstruation.
Chromosomal analysis has been suggested for patients diagnosed prenatally with MCDK. 30 The physical characteristics of our patients with MCDK do not support routine use of prenatal chromosomal analysis. Expecting parents should be counseled regarding the associated risk of nonspecific anomalies.
Patients presenting to our tertiary care center after age 2 years may differ from those referred at birth. Important differences between the 2 groups merit discussion. Fewer congenital anomalies were found in patients who presented after age 2 years. This finding may be due to poor data quality in the medical records, and perhaps other anomalies were more likely to be mentioned around birth. Three times as many patients in the older group had involution at diagnosis, which is consistent with the notion that involution occurs in most patients by age 3 years. The trajectory of kidney lengths between the 2 cohorts did not differ significantly ( fig. 3) , which suggests that their kidney lengths were on par with patients in the birth cohort. Because these cohorts could differ in unmeasured ways, we adjusted for cohort status in all the GEE models.
We use kidney length as a surrogate for kidney function. Creatinine clearance, although trending to significance, did not statistically differ between those with and without contralateral hypertrophy. This analysis was done in a small subset of patients and should be replicated. Patients in our sample who underwent a blood draw may have lower creatinine clearance than those who were monitored clinically, and may not represent the entire MCDK population. Not all patients had equal followup times, which presents opportunities for selection bias, especially regarding those with and without voiding cystourethrogram data. Despite these limitations, we provide evidence that not all patients with MCDK are the same, and these results have implications for differential followup in this population.
CONCLUSIONS
In our large cohort with MCDK renal length percentiles were defined by age (supplementary table 2, http://jurology.com/). Most children with MCDK will have contralateral hypertrophy by age 3 years. MCDK involution predicts contralateral kidney growth rate after age 2 years. A small minority of patients (approximately 10%) whose MCDK does not involute early in life do not manifest compensatory hypertrophy and are at risk for renal insufficiency. Patients without contralateral hypertrophy by age 3 years should undergo continued followup to assess for normal renal function.
